echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > New small molecules can effectively reduce neuroinflammation in the brain and glial cells

    New small molecules can effectively reduce neuroinflammation in the brain and glial cells

    • Last Update: 2021-09-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In a preclinical study published in the journal Glia, Dr.


    Glial cells are non-neuronal cells of the central nervous system (CNS) that help support and protect neurons


    King and Nabors are both professors in the Department of Neurology at the University of Alabama at Birmingham.


    Neuroinflammation occurs when the activated microglia and astrocytes in the brain or spine secrete cytokines and chemokines such as il-1β, IL-6, TNF-α, iNOS, CXCL1 and CCL2


    The colleagues of King, Nabors, and UAB have previously demonstrated that HuR, an RNA regulatory protein that binds to AREs, plays a major active role in regulating the production of inflammatory cytokines, making it the main control point of neuroinflammation


    HuR is usually concentrated in the nucleus of glial cells


    In previous work, UAB researchers showed that in acute central nervous system diseases, spinal injuries, and strokes, HuR tends to be located outside the nucleus of astrocytes


    It is important that HuR monomer cannot pass through the nuclear membrane, which is the regulatory membrane barrier between the nucleus and the cytoplasm


    In the current study, Dr.


    In addition, SRI-42127 inhibits the activation of mouse brain microglia and attenuates the recruitment of immune cells, neutrophils and monocytes from outside the blood-brain barrier into the central nervous system


    "Our findings," King and Nabors said, "emphasize the key role of HuR in promoting glial activation and the potential of SRI-42127 and other HuR inhibitors to treat neurological diseases caused by this activation


    In an unpublished study in collaboration with Dr.


    Any potential clinical treatment in the future requires skill


    "Therapeutic targeting of glial cells in central nervous system diseases is a balancing act, because these cells also play a role in neuroprotection and neuroplasticity, depending on the recovery stage of central nervous system damage or the stage of neurodegenerative diseases ," King and Nabors said


    In the current study, co-authors with King, Nabors and Filippova, "SRI-42127, a new small molecule inhibitor of the RNA regulator HuR, effectively attenuates glial activation in a model of lipopolysaccharide-induced neuroinflammation," They are Rajeshwari Chellappan, Abhishek Guha, Ying Si, Thaddaeus Kwan, Xiuhua Yang, Anish S.


    Support comes from the National Institutes of Health NS092651 and NS111275-01, and the U.


    In their long-term collaboration, King and Nabors used glioblastoma (a primary brain cancer) as a disease model to study HuR, because many factors that drive neuroinflammation also promote the growth of glioblastoma
    .
    Nabors focuses on the tumor suppressor properties of SRI-42127 and its potential application in the treatment of glioblastoma and other cancers
    .

    Journal Reference :

    1. Rajeshwari Chellappan, Abhishek Guha, Ying Si, Thaddaeus Kwan, Louis B.
      Nabors, Natalia Filippova, Xiuhua Yang, Anish S.
      Myneni, Shriya Meesala, Ashley S.
      Harms, Peter H.
      King.
      SRI ‐42127, a novel small molecule inhibitor of the RNA regulator HuR, potently attenuates glial activation in a model of lipopolysaccharide-induced neuroinflammation .
      Glia , 2021; DOI: 10.
      1002/glia.
      24094


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.